FindTrial
Sign In

AK112 Injection

DRUG5 trials

Sponsors

Summit Therapeutics, Sun Yat-sen University, Akeso

Conditions

Advanced Breast CancerAdvanced Non Small Cell Lung Cancer (NSCLC)Brain MetastasasesNSCLCNon-Squamous Non-small Cell Lung CancerUrothelial Carcinoma (UC)

Phase 2

A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
Not yet recruitingNCT06684873
Sun Yat-sen UniversityBrain Metastasases, NSCLC
Start: 2024-11-02End: 2027-12-01Target: 55Updated: 2024-11-12
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
RecruitingNCT07591090
AkesoAdvanced Breast Cancer
Start: 2026-07-17End: 2029-02-04Target: 200Updated: 2026-07-22
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma
Not yet recruitingNCT07636772
AkesoUrothelial Carcinoma (UC)
Start: 2026-06-22End: 2028-08-24Target: 132Updated: 2026-06-09
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
RecruitingNCT07669779
AkesoAdvanced Non Small Cell Lung Cancer (NSCLC)
Start: 2026-07-10End: 2029-05-30Target: 348Updated: 2026-07-14

Phase 3

Phase III Study of AK112 for NSCLC Patients
Active, not recruitingNCT06396065
Summit TherapeuticsNon-Squamous Non-small Cell Lung Cancer
Start: 2023-05-04End: 2026-12-31Updated: 2026-03-24